NSRX vs NVCT

Nasus Pharma Ltd. vs Nuvectis Pharma, Inc. — Valuation Comparison 2026

NSRX

Pharmaceutical Preparations
Nasus Pharma Ltd.
Quality
1.9
out of 10
Value Trap
Price
$3.36
Last close
Models
7/13
Active
VS

NVCT

Pharmaceutical Preparations
Nuvectis Pharma, Inc.
Quality
3.8
out of 10
Value Trap
18
SAFE
Price
$9.75
Last close
Models
6/13
Active

Model-by-Model Comparison

ModelType NSRX Fair ValueNSRX Upside NVCT Fair ValueNVCT Upside
Bayesian DCF Intrinsic $0.78 -76.9% $3.41 -65.0%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $0.15 -95.4% $1.15 -88.2%
PWERM Option-Based $2.27 -32.4% $10.59 +8.7%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for NSRX vs NVCT — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

NSRX vs NVCT — Which Stock Is More Undervalued?

NVCT scores higher with a 3.8/10 quality rating vs NSRX's 1.9/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Nasus Pharma Ltd. (NSRX) and Nuvectis Pharma, Inc. (NVCT) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

NSRX currently trades at $3.36 with a QOC of 1.9/10, while NVCT trades at $9.75 with a QOC of 3.8/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).